prezalumab (AMG 557) - Amgen, AstraZeneca
AstraZeneca: Q1 FY 2016 Update (AstraZeneca) - Apr 30, 2016 - Anticipated top-line results from P1 trial (NCT01683695) in SLE and lupus related inflammatory arthritis in Q2 2016 
Anticipated P1 data Immunology
https://www.astrazeneca.com/content/dam/az/press-releases/2016/Clinical_trials_appendix_Q1_2016_update.pdf
 
Apr 30, 2016
 
 
5ec6187a-dedf-41bd-aa26-aa78694a70f7.jpg